[{"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-001", "question": "A 45-year-old with severe ARDS on VV-ECMO develops suspected heparin-induced thrombocytopenia (4T score 6). Heparin is discontinued and argatroban initiated. The patient has significant hemolysis (plasma free hemoglobin 800 mg/dL). Which monitoring assay is most reliable for titrating argatroban in this setting?", "options": ["Activated partial thromboplastin time (aPTT)", "Anti-Xa chromogenic assay", "Anti-IIa (thrombin) chromogenic assay", "Activated clotting time (ACT)", "Dilute Russell viper venom time (dRVVT)"], "answer": "C", "answer_index": 2, "explanation": "Anti-IIa chromogenic assay directly measures thrombin inhibition by argatroban and is least affected by hemolysis, platelet count, or factor consumption seen in ECMO. aPTT is unreliable due to factor deficiency and hemolysis. Anti-Xa assays measure anti-Xa activity, not direct thrombin inhibitors. ACT is affected by platelets and fibrinogen. dRVVT is used for lupus anticoagulant detection.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "The clinical scenario describes a patient with ARDS on VV-ECMO who has developed HIT and is being treated with argatroban. The patient also has significant hemolysis (plasma free hemoglobin 800 mg/dL).\n\n1.  Standard Monitoring and Limitations: Argatroban is a direct thrombin inhibitor (DTI), traditionally monitored using the aPTT. However, in critically ill patients, especially those with severe ARDS and on ECMO, the aPTT is often unreliable.\n    *   Biological Interference: Severe inflammation (ARDS) leads to elevated levels of acute-phase reactants, particularly Factor VIII and fibrinogen. Elevated Factor VIII shortens the aPTT, causing a \"resistance\" pattern where therapeutic levels of argatroban do not prolong the aPTT to the target range. This can lead to dangerous over-dosing if one titrates solely based on aPTT.\n    *   Analytical Interference: While the question mentions significant hemolysis, which can interfere with optical clot detection in broad coagulation tests like the aPTT, the primary driver for switching assays in this specific clinical profile (ARDS/ECMO/HIT) is the biological unreliability of the aPTT.\n\n2.  Alternative Assays:\n    *   ACT (Option D): Activated Clotting Time is used for bedside monitoring of high-dose anticoagulation (like heparin in ECMO/CPB). However, it correlates poorly with argatroban at the lower doses used for HIT treatment and is not sensitive enough for precise titration.\n    *   Anti-Xa (Option B): This assay monitors Factor Xa inhibition (e.g., LMWH, oral Xa inhibitors). Argatroban inhibits Factor IIa (thrombin), not Xa, so this assay is not applicable.\n    *   dRVVT (Option E): This is a diagnostic test for Lupus Anticoagulant, not a monitoring assay for drug titration.\n    *   Anti-IIa (thrombin) chromogenic assay (Option C): Direct Thrombin Inhibitor assays (such as the Ecarin Chromogenic Assay or diluted Thrombin Time, often grouped under anti-IIa monitoring) specifically measure the activity of the drug (thrombin inhibition) rather than the global clotting time.\n        *   These assays are unaffected by Factor VIII levels or Lupus Anticoagulants, making them the \"gold standard\" or rescue assay when aPTT is confounded.\n        *   While hemolysis can cause spectral interference in chromogenic assays (which typically read at 405 nm), validated chromogenic anti-IIa assays (specifically the Ecarin Chromogenic Assay) are often robust or have higher tolerance thresholds for hemoglobin compared to standard optical clotting assays. More importantly, they provide a direct measure of the drug level, bypassing the hypercoagulable noise of the extrinsic/intrinsic pathways present in the patient.\n\nGiven the unreliability of aPTT in severe inflammatory states and ECMO, the specific measurement of drug effect via an anti-IIa assay is the most reliable method for titration.\n\nThe answer is (C)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-002", "question": "A 62-year-old with metastatic pancreatic adenocarcinoma on gemcitabine presents with acute kidney injury (creatinine 3.2 mg/dL), platelet count 45,000/µL, schistocytes, LDH 2200 IU/L, and haptoglobin <10 mg/dL. ADAMTS13 activity is 35%. What is the most appropriate initial management?", "options": ["Urgent plasma exchange", "Eculizumab therapy", "Discontinue gemcitabine and provide supportive care", "Rituximab 375 mg/m² weekly", "Caplacizumab 10 mg daily"], "answer": "C", "answer_index": 2, "explanation": "Gemcitabine-induced thrombotic microangiopathy is a drug-mediated toxicity, not complement-mediated or immune-mediated. ADAMTS13 is not severely deficient (<10%), excluding TTP. Plasma exchange is ineffective. Eculizumab and caplacizumab are reserved for complement-mediated aHUS. Rituximab is for TTP. The cornerstone of management is immediate discontinuation of gemcitabine.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "This patient presents with signs of thrombotic microangiopathy (TMA): microangiopathic hemolytic anemia (schistocytes, elevated LDH, low haptoglobin), thrombocytopenia, and acute kidney injury. The ADAMTS13 activity is 35%, which rules out Thrombotic Thrombocytopenic Purpura (TTP), as TTP is defined by an activity level of <10%. Consequently, treatments specific to TTP, such as plasma exchange (Option A), rituximab (Option D), and caplacizumab (Option E), are not the primary indicated interventions.\n\nThe patient is receiving gemcitabine, a chemotherapeutic agent well-known to cause drug-induced TMA (DITMA), often manifesting as Hemolytic Uremic Syndrome (HUS). Gemcitabine-associated TMA is typically cumulative and dose-dependent. The mainstay of management for gemcitabine-induced TMA is the immediate discontinuation of the drug. Unlike TTP or some forms of immune-mediated TMA, gemcitabine-induced TMA generally does not respond to therapeutic plasma exchange. While Eculizumab (Option B) has been used in some refractory cases of drug-induced TMA or atypical HUS, it is not the first-line standard of care, especially before the offending agent has been withdrawn and the clinical course evaluated. Therefore, stopping the medication and providing supportive care (dialysis, hypertension management, transfusion support) is the most appropriate initial step.\n\nThe answer is (C)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-003", "question": "A 28-year-old presents 2 hours after ingesting barium carbonate with profuse vomiting, diarrhea, and profound muscle weakness. Serum potassium is 2.1 mEq/L with ST-segment depression on ECG. What is the primary mechanism of hypokalemia and most effective elimination strategy?", "options": ["GI losses; emergent hemodialysis", "Intracellular shift via K+ channel blockade; oral sodium sulfate", "Renal tubular wasting; potassium-sparing diuretics", "Beta-agonist effect; beta-blockade therapy", "Insulin-mediated shift; IV insulin with glucose"], "answer": "B", "answer_index": 1, "explanation": "Barium blocks voltage-gated potassium channels (Kv), preventing cellular efflux and causing intracellular K+ sequestration. Hemodialysis is ineffective due to barium's large volume of distribution (1.5 L/kg). Oral sodium sulfate precipitates residual Ba2+ as insoluble BaSO4 in the GI tract if administered within 24 hours, preventing further absorption. Massive IV potassium replacement is necessary but does not address elimination.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "Here is a step-by-step analysis of the question:\n\n1.  Identify the Toxin and Clinical Picture: The patient ingested barium carbonate (a soluble barium salt, often found in rodenticides or ceramic glazes). The symptoms include vomiting, diarrhea, and profound muscle weakness. The key lab finding is severe hypokalemia (2.1 mEq/L).\n\n2.  Determine the Mechanism of Hypokalemia:\n    *   Soluble barium ions ($Ba^{2+}$) are potent blockers of membrane potassium channels, specifically the inward rectifier potassium channels ($K_{ir}$) that allow potassium to passively diffuse out of the cell.\n    *   The sodium-potassium ATPase pump ($Na^+/K^+$ pump) continues to actively transport potassium *into* the cells.\n    *   Because the exit channels are blocked, potassium becomes trapped intracellularly. This results in a massive intracellular shift of potassium, causing severe serum hypokalemia. While vomiting and diarrhea (GI losses) occur, the rapid and profound drop in potassium is primarily due to this shift, not excretion.\n\n3.  Identify the Effective Elimination/Treatment Strategy:\n    *   The specific \"antidote\" or decontamination strategy for barium poisoning is the administration of a soluble sulfate salt, such as sodium sulfate or magnesium sulfate.\n    *   When sulfate ions ($SO_4^{2-}$) encounter barium ions ($Ba^{2+}$) in the gastrointestinal tract, they react to form barium sulfate ($BaSO_4$).\n    *   Barium sulfate is insoluble and non-toxic (it is the same compound used in radiographic contrast studies). This reaction prevents further absorption of the barium and allows it to be eliminated safely in the stool.\n    *   While hemodialysis can be used in refractory cases or in patients with renal failure, the most specific and immediate pharmacological intervention to prevent absorption and facilitate removal of the toxic ions from the GI tract is the administration of sulfates. Moreover, the mechanism paired with hemodialysis in Option A (GI losses) is incorrect regarding the primary cause of hypokalemia.\n\n4.  Evaluate the Options:\n    *   A. Incorrect mechanism (GI losses are minor compared to the shift).\n    *   B. Correct mechanism (Intracellular shift via K+ channel blockade) and correct specific strategy (oral sodium sulfate to precipitate barium).\n    *   C. Incorrect mechanism (not renal wasting).\n    *   D. Incorrect mechanism (not a beta-agonist effect).\n    *   E. Incorrect mechanism (not insulin-mediated); insulin would worsen the condition.\n\nThe answer is (B)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-004", "question": "A 3-month-old infant presents with intractable seizures, hypotonia, and developmental regression. Brain MRI shows bilateral globus pallidus hyperintensity. Plasma creatine level is low. Which test provides the most specific diagnosis for guanidinoacetate methyltransferase (GAMT) deficiency?", "options": ["Plasma guanidinoacetate measurement", "Urine creatine:creatinine ratio", "Cerebrospinal fluid guanidinoacetate level", "GAMT gene sequencing", "Brain magnetic resonance spectroscopy"], "answer": "C", "answer_index": 2, "explanation": "CSF guanidinoacetate is the most sensitive and specific biomarker for GAMT deficiency due to accumulation behind the blood-brain barrier. Plasma GAA can be normal in mild cases. Urine ratio is supportive but nonspecific. GAMT sequencing may miss deep intronic variants or large deletions. MRS shows absent creatine peak but does not identify the specific enzyme defect.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "The clinical presentation of intractable seizures, hypotonia, developmental regression, and low plasma creatine is characteristic of a Cerebral Creatine Deficiency Syndrome (CCDS). The MRI finding of bilateral globus pallidus hyperintensity is specifically pathognomonic for Guanidinoacetate Methyltransferase (GAMT) deficiency, caused by the accumulation of guanidinoacetate (GAA), which is providing a toxic effect on the basal ganglia.\n\nTo distinguish between the types of creatine deficiency syndromes (AGAT, GAMT, and Creatine Transporter deficiency):\n1.  Creatine Transporter (SLC6A8) Deficiency: Plasma creatine is typically normal. Urine creatine-to-creatinine ratio is elevated.\n2.  Arginine:Glycine Amidinotransferase (AGAT) Deficiency: Plasma creatine is low. Plasma guanidinoacetate is low (as the block is before its formation).\n3.  Guanidinoacetate Methyltransferase (GAMT) Deficiency: Plasma creatine is low (as seen in the patient). Plasma guanidinoacetate is markedly elevated (due to the block in the conversion of GAA to creatine).\n\nTherefore, the measurement of guanidinoacetate (GAA) concentrations in plasma (or urine/CSF) is the biochemical test that provides the most specific diagnosis, distinguishing GAMT deficiency from AGAT deficiency and other causes. While gene sequencing (Option D) confirms the diagnosis at the molecular level, the detection of the specific accumulated metabolite (GAA) is the diagnostic hallmark and the direct functional readout of the enzyme deficiency. In the context of multiple-choice questions regarding metabolic errors, the identification of the pathognomonic metabolite is typically the correct answer for the \"diagnostic test.\"\n\nOption A is the best answer because elevated plasma guanidinoacetate is distinctive and diagnostic for GAMT deficiency in the setting of low creatine.\n\nThe answer is (A)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-005", "question": "A 58-year-old develops progressive non-REM parasomnia, obstructive sleep apnea, bulbar dysfunction, and gait ataxia over 18 months. CSF shows mild lymphocytic pleocytosis. Which antibody and pathological finding are most characteristic?", "options": ["Anti-Hu; neuronal nuclear inclusions", "Anti-NMDA receptor; perivascular lymphocytic cuffing", "Anti-IgLON5; tau deposition in brainstem and hypothalamus", "Anti-LGI1; faciobrachial dystonic seizures", "Anti-GAD65; cerebellar Purkinje cell loss"], "answer": "C", "answer_index": 2, "explanation": "Anti-IgLON5 disease presents with sleep dysfunction (non-REM parasomnia, obstructive apnea) and bulbar symptoms, distinct from other autoimmune encephalitides. Unlike typical antibody-mediated diseases, it is characterized by tauopathy (4R-tau deposition) in the brainstem and hypothalamus on autopsy, correlating with poor response to immunotherapy. Anti-Hu is associated with small cell lung cancer and sensory neuropathy. Anti-LGI1 presents with faciobrachial dystonic seizures and hyponatremia.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "This patient presents with a distinctive cluster of symptoms: progressive non-REM parasomnia, obstructive sleep apnea (OSA), bulbar dysfunction, and gait ataxia. This specific constellation is characteristic of anti-IgLON5 disease.\n\nHere is a breakdown of the reasoning:\n\n1.  Clinical Presentation: Anti-IgLON5 disease often presents with a prominent sleep disorder comprising non-REM parasomnias (which are rare in other conditions compared to REM behavior disorder), sleep-disordered breathing (OSA and stridor), and insomnia. Patients also frequently develop bulbar symptoms (dysphagia, dysarthria), gait instability (ataxia), and features resembling progressive supranuclear palsy (PSP).\n2.  Pathology: Anti-IgLON5 disease is unique because it challenges the traditional dichotomy between autoimmune and neurodegenerative disorders. While it is associated with antibodies against a neuronal cell surface protein (IgLON5), neuropathological examination reveals neuronal loss and gliosis accompanied by neurofibrillary accumulation of hyperphosphorylated tau (3-repeat and 4-repeat), predominantly involving the hypothalamus and the brainstem tegmentum.\n3.  Other Options:\n    *   Anti-Hu (A) is associated with paraneoplastic sensory neuronopathy and encephalomyelitis (often limbic or cerebellar) related to small-cell lung cancer. It is not characterized by this specific sleep phenotype or nuclear inclusions.\n    *   Anti-NMDA receptor (B) encephalitis typically presents in younger patients with psychiatric symptoms, seizures, and dyskinesias.\n    *   Anti-LGI1 (D) is classically associated with limbic encephalitis and faciobrachial dystonic seizures, not the sleep/bulbar phenotype described.\n    *   Anti-GAD65 (E) is associated with Stiff-Person Syndrome and cerebellar ataxia, but not the specific non-REM parasomnia and tauopathy described here.\n\nThe answer is (C)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-006", "question": "During VV-ECMO for severe ARDS, the circuit suddenly shows extensive air with the patient becoming pulseless. What is the immediate management step?", "options": ["Place patient in left lateral decubitus and Trendelenburg position while continuing pump", "Clamp venous line, stop pump, aspirate from arterial port", "Increase ECMO flow to 6 L/min to clear air emboli", "Administer 100% oxygen and initiate CPR", "Convert circuit to VA-ECMO configuration"], "answer": "B", "answer_index": 1, "explanation": "In VV-ECMO, air embolism is venous. The immediate action is to stop the pump to halt further embolization, clamp the venous line to prevent additional air entry, and aspirate air from the arterial (outflow) line port. Durant's position is ineffective for venous emboli. Increasing pump flow worsens embolization. CPR is secondary to circuit management. Configuration change does not address the acute air emergency.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "Here is the step-by-step analysis:\n\n1.  Identify the Emergency: The scenario describes a massive air embolism in a patient on VV-ECMO, evidenced by air in the circuit and the patient becoming pulseless.\n2.  Pathophysiology: Air has entered the venous drainage or the circuit, passed through the pump, and is being (or has been) returned to the patient's venous system. From there, it travels to the right ventricle. A large bolus of air in the right ventricle can caused an \"air lock,\" obstructing outcome to the pulmonary artery, leading to cardiovascular collapse (pulselessness).\n3.  Immediate Goal: The primary objective is to prevent further air from entering the patient and to manage the existing air lock.\n4.  Analyze Options:\n    *   A. Place patient in left lateral decubitus and Trendelenburg position while continuing pump: Positioning (Durant maneuver) is correct to trap air in the right ventricle apex and prevent it from obstructing the pulmonary outflow tract or crossing a PFO. However, continuing the pump is fatal as it continues to infuse air. This makes the option incorrect.\n    *   B. Clamp venous line, stop pump, aspirate from arterial port: This describes the definitive management of the circuit. The first priority is to stop the mechanism of injury. This involves clamping the lines (to isolate the patient from the circuit) and stopping the pump. Once the circuit is isolated and the pump is stopped, attempts can be made to aspirate air from the circuit (de-airing) via the arterial (return) port/line or from the patient's central line/heart. This is the correct management sequence for the device.\n    *   C. Increase ECMO flow: This would pump more air into the patient, worsening the condition. Incorrect.\n    *   D. Administer 100% oxygen and initiate CPR: While the patient is pulseless and requires resuscitation, and 100% oxygen (on the ventilator) is helpful to reduce the size of nitrogen-based bubbles, this option fails to address the active failure of the ECMO circuit. If the pump is not stopped, the embolism continues. Therefore, circuit management (Option B) is the specific \"immediate management step\" required by the context of the exam question regarding the ECMO complication.\n    *   E. Convert to VA-ECMO: This is a time-consuming procedure and does not address the immediate crisis of air embolism.\n\n5.  Conclusion: The most critical immediate action is to stop the pump and clamp the lines to prevent further embolization, followed by de-airing.\n\nThe answer is (B)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-007", "question": "A 22-year-old with relapsed ALL receives axicabtagene ciloleucel. On day 12, he develops status epilepticus and CT shows cerebral edema, unresponsive to methylprednisolone 1 g/day for 3 days. What is the most appropriate next therapy for steroid-refractory ICANS?", "options": ["Increase methylprednisolone to 2 g/day", "Anakinra 100 mg intravenously", "Tocilizumab 8 mg/kg intravenously", "Cyclophosphamide 500 mg/m²", "Therapeutic plasma exchange"], "answer": "B", "answer_index": 1, "explanation": "Anakinra, an IL-1 receptor antagonist, is the preferred therapy for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS). Tocilizumab targets IL-6 and is effective for cytokine release syndrome but has limited efficacy for ICANS. Escalating steroids beyond 1 g/day provides minimal additional benefit. Cyclophosphamide is not used for ICANS. Plasma exchange would eliminate the therapeutic CAR-T cells.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "This patient has severe Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), characterized by status epilepticus and cerebral edema, which has proven refractory to high-dose corticosteroids (methylprednisolone 1 g/day).\n\n1.  Diagnosis: The clinical presentation of neurotoxicity (seizures, edema) following CAR T-cell therapy, specifically axicabtagene ciloleucel, is defined as ICANS. Since it persists despite aggressive steroid treatment, it is classified as steroid-refractory ICANS.\n2.  Pathophysiology: Research suggests that IL-1 plays a significant role in the pathophysiology of ICANS, particularly in cases of severe neurotoxicity where extensive myeloid activation occurs.\n3.  Treatment Guidelines:\n    *   Tocilizumab (Option C) is an IL-6 receptor antagonist used primarily for Cytokine Release Syndrome (CRS). It is generally not recommended for ICANS in the absence of concurrent CRS because it does not cross the blood-brain barrier effectively and may transiently increase serum IL-6 levels, potentially worsening neurotoxicity.\n    *   Increasing steroids (Option A) is unlikely to be effective given the patient has already failed pulse-dose methylprednisolone (1 g/day).\n    *   Anakinra (Option B) is a recombinant IL-1 receptor antagonist. Current guidelines (e.g., NCCN, ASCO, SITC) and expert consensus recommend Anakinra as the next line of therapy for steroid-refractory ICANS. It targets the IL-1 pathway implicated in the neurotoxicity.\n    *   Cyclophosphamide (Option D) is a chemotherapy agent that can ablate CAR T cells. While it acts as a salvage therapy in extreme cases to stop the immune response by killing the effector cells, Anakinra is the preferred pharmacological escalation for immunosuppression prior to T-cell ablation.\n    *   Therapeutic Plasma Exchange (Option E) is not a standard treatment for ICANS.\n\nTherefore, the administration of Anakinra is the most appropriate next step in management.\n\nThe answer is (B)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-008", "question": "A 35-year-old presents with refractory shock (BP 70/40) and bradycardia (HR 40) after ingesting 10 g of sustained-release verapamil. High-dose insulin euglycemic therapy (HIET) is initiated. What is the optimal insulin dosing and monitoring frequency?", "options": ["0.5-1 unit/kg/hr; check glucose every 2 hours", "1-10 units/kg/hr; check glucose every hour", "0.1-0.5 units/kg/hr; check potassium every 4 hours", "5-20 units/kg/hr; check lactate every 2 hours", "2-5 units/kg/hr; check pH every 4 hours"], "answer": "B", "answer_index": 1, "explanation": "HIET for severe calcium channel blocker overdose requires supraphysiologic insulin doses of 1-10 units/kg/hr to overcome insulin resistance and maximize myocardial glucose uptake. Blood glucose must be monitored hourly to maintain euglycemia (150-200 mg/dL) with concurrent dextrose infusion. Lower doses are ineffective. Doses exceeding 10 units/kg/hr are not standard practice. Potassium and pH are monitored but glucose is the critical parameter.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "This question addresses the management of severe calcium channel blocker (CCB) toxicity, specifically the administration of High-dose Insulin Euglycemic Therapy (HIET).\n\n1.  Indication: The patient has ingested a massive amount of verapamil (10 g) and is in refractory shock despite initial measures (implied by the term \"refractory\"). HIET is a first-line inotrope strategy for severe CCB toxicity.\n2.  Dosing:\n    *   Loading Dose: Standard protocol usually begins with an IV bolus of 1 unit/kg of regular insulin.\n    *   Maintenance Infusion: The infusion typically starts at 1 unit/kg/hr.\n    *   Titration: If the patient remains hemodynamically unstable, the insulin infusion rate should be titrated up. It is often increased every 15–30 minutes. The effective dose range described in toxicology literature generally falls between 1 and 10 units/kg/hr. Some cases have required doses as high as 10 units/kg/hr to achieve hemodynamic stability.\n3.  Monitoring:\n    *   Glucose: Insulin causes profound hypoglycemia. Glucose must be monitored very frequently. Protocols dictate checking glucose every 15–30 minutes initially, and once stable, every hour. Checking every 2 hours (Option A) is unsafe.\n    *   Potassium: Insulin shifts potassium intracellularly, causing hypokalemia. Potassium should also be monitored hourly initially.\n\nAnalysis of Options:\n*   A (0.5-1 unit/kg/hr; check glucose every 2 hours): The dosing is on the lower end of the HIET spectrum (often just the starting point), but the limiting factor here is the monitoring frequency. Checking glucose every 2 hours is dangerous during high-dose insulin therapy.\n*   B (1-10 units/kg/hr; check glucose every hour): This option correctly identifies the broad therapeutic infusion range (1 up to 10 units/kg/hr for refractory cases) and mandates the appropriate safety monitoring interval for hypoglycemia (every hour).\n*   C (0.1-0.5 units/kg/hr...): This dosing is typical for DKA or hyperkalemia management, not CCB toxicity. It is insufficient for the inotropic support needed in overdose.\n*   D (5-20 units/kg/hr...): While doses can get high, starting/ranging primarily at 5-20 is not the standard stepwise approach, and lactate is not the primary safety monitor for the insulin infusion itself.\n*   E (2-5 units/kg/hr...): While the dose falls within the therapeutic range, pH monitoring is not the specific safety check for HIET complications.\n\nTherefore, Option B represents the most accurate dosing range for refractory shock and the correct monitoring safety profile.\n\nThe answer is (B)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-009", "question": "A 6-month-old male infant presents with severe eczema, petechiae, recurrent otitis media, and platelet count of 30,000/µL with small platelet volume. What is the most sensitive diagnostic test for Wiskott-Aldrich syndrome?", "options": ["WASP gene sequencing", "Platelet-associated antibody testing", "Lymphocyte subset enumeration", "WASP protein expression by flow cytometry", "Serum IgE and IgA levels"], "answer": "D", "answer_index": 3, "explanation": "Flow cytometry for WASP protein expression in lymphocytes is more sensitive than standard gene sequencing, which may miss large deletions, splice site mutations, or deep intronic variants. Absent or reduced WASP protein expression confirms the diagnosis. Platelet antibodies are negative. Lymphocyte subsets are variable. IgE is elevated and IgA is low but these are nonspecific.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "This 6-month-old infant presents with the classic triad of Wiskott-Aldrich Syndrome (WAS): eczema, thrombocytopenia (with small platelet volume), and immunodeficiency (recurrent otitis media). The finding of microthrombocytopenia (low mean platelet volume, MPV) is particularly characteristic and helps distinguish WAS from Immune Thrombocytopenic Purpura (ITP), where platelets are typically normal in size or large.\n\nThe condition is caused by a mutation in the *WAS* gene on the X chromosome, which encodes the Wiskott-Aldrich Syndrome Protein (WASP).\n\nAnalysis of the options:\n*   A. WASP gene sequencing: This is the definitive and most sensitive diagnostic test. It identifies the specific mutation in the *WAS* gene. It can detect mutations in over 98% of patients with the phenotype, including those with X-linked thrombocytopenia (XLT) who might have detectable (though often reduced) protein levels which could potentially be missed or misinterpreted by flow cytometry. It is considered the gold standard for confirmation.\n*   B. Platelet-associated antibody testing: This test is used to support a diagnosis of ITP. While patients with WAS can develop autoimmune cytopenias, this test does not diagnose WAS itself.\n*   C. Lymphocyte subset enumeration: Patients often develop lymphopenia (especially T-cell) over time, but this is a non-specific finding common to many immunodeficiencies.\n*   D. WASP protein expression by flow cytometry: This is a very useful, rapid screening test. In classic WAS, the protein is usually absent. However, in milder forms (XLT) or revertant mosaicism, the protein may be present/expressed. Because rare cases of WAS/XLT can express non-functional mutant protein (which would register as \"present\" on flow cytometry unless specific functional assays or quantitative intensity is strictly analyzed), gene sequencing is considered more sensitive and specific for establishing the diagnosis across the entire spectrum of the disorder.\n*   E. Serum IgE and IgA levels: Classically, WAS presents with low IgM, and elevated IgA and IgE. However, this pattern is variable, especially in infants, and is not sufficiently sensitive or specific to be the primary diagnostic test.\n\nTherefore, while flow cytometry is often the *best initial* test due to speed, gene sequencing is the *most sensitive* and confirmatory diagnostic test.\n\nThe answer is (A)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-010", "question": "A 28-year-old develops progressive myoclonus epilepsy, cerebellar ataxia, and visual loss over 3 years. EEG shows generalized spike-wave discharges. Which test is most specific for diagnosing Kufs disease (adult neuronal ceroid lipofuscinosis)?", "options": ["Epilepsy gene panel (SCN1A, GABRG2)", "Brain biopsy with periodic acid-Schiff staining", "Skin biopsy with electron microscopy", "CSF 14-3-3 protein immunoassay", "Serum anti-GAD65 antibody titer"], "answer": "C", "answer_index": 2, "explanation": "Electron microscopy of skin biopsy showing fingerprint profiles or granular osmiophilic deposits is the most specific diagnostic test for neuronal ceroid lipofuscinosis. Genetic testing (CLN6, CLN8, CTSF) is confirmatory but may be negative in variant forms. Brain biopsy is invasive and unnecessary. CSF 14-3-3 protein is elevated in Creutzfeldt-Jakob disease. Anti-GAD65 antibodies are associated with autoimmune epilepsy, not NCL.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "This patient presents with a syndrome of progressive myoclonus epilepsy (PME). The differential diagnosis for adult-onset PME includes Lafora body disease, Unverricht-Lundborg disease, Neuronal Ceroid Lipofuscinoses (NCLs) like Kufs disease, Sialidosis, and MERRF (Myoclonic Epilepsy with Ragged Red Fibers).\n\nThe question specifically asks for the test most specific for diagnosing Kufs disease (Adult Neuronal Ceroid Lipofuscinosis).\n\n1.  Pathophysiology: NCLs are lysosomal storage disorders characterized by the intracellular accumulation of excessive amounts of autofluorescent lipopigments (ceroid and lipofuscin).\n2.  Diagnostic Testing:\n    *   Genetics: While genetic panels are now often the first line, Option A lists *SCN1A* and *GABRG2*. These genes are associated with genetic epilepsy syndromes like Dravet syndrome or GEFS+, not the CLN genes (*CLN6*, *PPT1/CLN1*, *DNAJC5/CLN4*, *CTSD/CLN10*, etc.) associated with Kufs disease.\n    *   Biopsy: Because the storage material accumulates in tissues outside the CNS, a peripheral tissue biopsy is a standard diagnostic tool when genetics is unavailable or inconclusive. Skin biopsy is the preferred minimally invasive method.\n    *   Visualization: The biopsy of the skin (specifically looking at eccrine sweat gland epithelial cells, vascular smooth muscle, or Schwann cells) is examined using electron microscopy (EM). In Kufs disease, EM typically reveals characteristic ultrastructural patterns such as fingerprint profiles, rectilinear profiles, or granular osmiophilic deposits (GRODs).\n    *   Option B (Brain biopsy): While a brain biopsy would show the pathology, it is highly invasive and reserved for cases where peripheral biopsies and genetics are non-diagnostic.\n    *   Option D (14-3-3): This is a marker for Creutzfeldt-Jakob Disease (CJD).\n    *   Option E (Anti-GAD65): This is associated with Stiff-Person Syndrome and autoimmune cerebellar ataxia, not NCL.\n\nAlthough classic Kufs disease often spares vision (unlike childhood NCLs), the question asks specifically for the diagnostic test for the condition. Skin biopsy with EM is the correct method to identify the pathognomonic lysosomal inclusions.\n\nThe answer is (C)"}]